Catalent Bolsters Drug Development Capabilities
Catalent Pharma Solutions has unveiled plans to invest $5 million in the creation of a new drug development center of excellence (CoE) at its Somerset, NJ facility and headquarters. The investment will see the site focus on preclinical to clinical phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules. It will also build upon the site's expertise in the development of modified release formulation, bioavailability solutions, the application of OptiMelt hot melt extrusion (HME) technology, and its status as the company's CoE for handling potent compounds and controlled substances.
"This latest investment in Somerset will significantly strengthen our early development offering with focused formulation expertise and capacity for additional speed and flexibility," said Jonathan Arnold, president of Catalent's oral drug delivery business unit. "It is highly complementary to Catalent's West Coast facility in San Diego, CA and further positions Catalent as the strategic partner of choice for the early development of solid oral dose forms."
Catalent's 265,000 square-foot headquarters and development center in Somerset has a long track record of successfully developing, launching, and manufacturing many oral treatments for leading global innovators. The site features state-of-the-art analytical labs, pilot and clinical scale equipment including HME and fluid bed processing, and significant expertise in coating technologies, capsules, tablets, minitablets, and multi-particulates.
Catalent's early phase drug development sites are closely connected to Catalent's clinical supply services network, to optimize transition from finished dose manufacture to clinical packaging and distribution. In addition, the Somerset facility will offer seamless transfers to Catalent's integrated commercial manufacturing network in: Kansas City, MO; Winchester, KY; Swindon, UK; and Schorndorf, Germany, for later stage clinical trials using compatible, scalable equipment.
Looking for chemical products? Let suppliers reach out to you!
AMRI Renews NIH Contract
2026-07-13
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Pharma Quality Excellence Awards 2026 - Celebration and Conclusion
-
Pharma Quality Reimagined: Highlights from the 6th Annual Pharma GMP & Quality Management 2026
-
From Feedmill to Food System: VIV Europe 2026 Addresses the Industry's Most Critical Challenges
-
Beyond Compliance: Building Quality Maturity
-
Catalent Faces Continuous Losses and Operational Challenges in 2023, Reports $715 Million Net Loss in Q1 2024
-
Is the class solidified? From Biotech to Pharma
-
The IPO of the Largest Domestic Metronidazole API Manufacturer has Passed the Meeting
-
Progesterone Market Potential is Huge
-
PharmaReg AfriSummit
-
2022 PHARMA X FOOD X FINE CHEMICAL RAW MATERIALS MATCH MEETING Successfully Held!
Recommend Reading
-
BASF’s Price Increase Shows Pharma Excipients Are Still Exposed to Chemical Cost Pressure
-
FDA’s Warning to Compounders Raises the Stakes for API and Excipient Suppliers
-
Lilly’s Indiana Investment Puts API Capacity at the Center of Obesity Drug Competition
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain
-
API Supplier Audits Move to the Center of Pharma Supply Resilience
-
Supply-side disruptions persist, lithium carbonate prices continue to rise
-
Trump’s Steel, Aluminum and Copper Tariff Changes Pull Chemical Manufacturing Into the Impact Zone
-
This week, the Chinese propylene oxide market shows a significant downward trend
-
EU Plans Broader Quotas and Tariffs on China, With Chemicals Clearly Named
-
This Round Sees the First Retail Price Drop for Refined Oil Products This Year